208 related articles for article (PubMed ID: 18410454)
21. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.
Sun D; Elson P; Liedtke M; Medeiros BC; Earl M; Alizadeh A; Bates J; Sekeres MA; Coutre S; Kalaycio M; Sobecks R; Copelan E; Advani AS
Am J Hematol; 2012 Oct; 87(10):957-60. PubMed ID: 22729847
[TBL] [Abstract][Full Text] [Related]
22. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
23. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
24. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
[TBL] [Abstract][Full Text] [Related]
25. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Franke N; Winter A; Tiedemann R; Kukreti V
Leuk Lymphoma; 2015; 56(9):2668-73. PubMed ID: 25573201
[TBL] [Abstract][Full Text] [Related]
26. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
27. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.
Kim H; Sohn HJ; Kim SE; Kang HJ; Park S; Kim S; Kim WK; Lee JS; Suh C
Bone Marrow Transplant; 2004 Jul; 34(1):43-9. PubMed ID: 15107814
[TBL] [Abstract][Full Text] [Related]
28. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
[TBL] [Abstract][Full Text] [Related]
29. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Wellik LA; Fonseca R; Lust JA; Witzig TE; Kyle RA; Greipp PR; Rajkumar SV
Bone Marrow Transplant; 2004 Aug; 34(3):235-9. PubMed ID: 15170170
[TBL] [Abstract][Full Text] [Related]
31. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
32. Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma.
Johnson ME; Zhu F; Li T; Wu H; Galloway TJ; Farma JM; Perlis CS; Turaka A
J Am Acad Dermatol; 2014 Jun; 70(6):1028-35. PubMed ID: 24666998
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.
Porrata LF; Ristow K; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
Br J Haematol; 2012 May; 157(3):321-30. PubMed ID: 22360654
[TBL] [Abstract][Full Text] [Related]
34. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas.
Behl D; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Porrata LF
Br J Haematol; 2007 Jun; 137(5):409-15. PubMed ID: 17433025
[TBL] [Abstract][Full Text] [Related]
35. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
36. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
37. Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma.
Yang Y; Liu Z; Wang H
Med Sci Monit; 2020 Jul; 26():e923716. PubMed ID: 32732863
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma.
Tiwari D; Gao F; Hidalgo J; Adkins DR; Vij R; DiPersio JF; Khoury HJ
Bone Marrow Transplant; 2007 Oct; 40(7):671-5. PubMed ID: 17680023
[TBL] [Abstract][Full Text] [Related]
39. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia.
Porrata LF; Litzow MR; Tefferi A; Letendre L; Kumar S; Geyer SM; Markovic SN
Leukemia; 2002 Jul; 16(7):1311-8. PubMed ID: 12094255
[TBL] [Abstract][Full Text] [Related]
40. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Porrata LF; Gertz MA; Inwards DJ; Litzow MR; Lacy MQ; Tefferi A; Gastineau DA; Dispenzieri A; Ansell SM; Micallef IN; Geyer SM; Markovic SN
Blood; 2001 Aug; 98(3):579-85. PubMed ID: 11468153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
